medigraphic.com

2007, Number S1

<< Back Next >>

Arch Cardiol Mex 2007; 77 (S1)

3. Cardiogenic shock after acute coronary syndrome without mechanical complications

Lupi HE, González PH

Language: Spanish
References: 36
Page: 34-38
PDF size: 67.12 Kb.


Text Extraction

No abstract


REFERENCES

  1. HOCHMAN JS: Cardiogenic Shock Complicating Acute Myocardial Infarction. Expanding the Paradigm. Circulation 2003; 107: 2998-3002.

  2. HOCHMAN JS, SLEEPER LA, WEBB JG, ET AL: Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 1999; 341: 625-634.

  3. GOLDBERG RJ, SAMAD NA, YARZEBSKI J, ET AL: Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 1999; 340: 1162-1168.

  4. LINDHOLM MG, KOBER L, BOESGAARD S, ET AL, on behalf of the TRACE study group: Cardiogenic shock complicating acute myocardial infarction. Prognostic impact of early and late shock development. Eur Heart J 2003; 24: 258-265.

  5. KILLIP T: Cardiogenic shock complicating myocardial infarction. J Am Coll Cardiol 1989; 14: 47-48.

  6. HOCHMAN JS, BULLER CE, SLEEPER LA, ET AL, for the SHOCK investigators: Cardiogenic shock complicating acute myocardial infarction. Etiologies, management and outcome: A report from the SHOCK trial registry. J Am Coll Cardiol 2000; 36: 1063-1070.

  7. ALONSO DR, SCHEIDT S, POST M, ET AL: Pathophysiology of cardiogenic shock: quantification of myocardial necrosis, clinical, pathologic and electrocardiographic correlations. Circulation 1973; 48: 588-596.

  8. HOLMES DR, BATES ER, KLEIMAN NS, ET AL: Contemporary reperfusion therapy for cardiogenic shock: The GUSTO-I trial experience. J Am Coll Cardiol 1995; 26: 668-674.

  9. HASDAI D, HARRINGTON RA, HOCHMAN JS, ET AL: Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. J Am Coll Cardiol 2000; 36: 685-692.

  10. HASDAI D, HOLMES DR, TOPOL EJ, ET AL: Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase: Results from GUSTO III. Eur Heart J 1999; 20: 128-135.

  11. HOLMES DR, BEGER PB, HOCHMAN JS, ET AL: Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. Circulation 1999; 100: 2067-2073.

  12. HASDAI D, CALIFF RM, THOMPSON TD, ET AL: Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 2000; 35: 136-143.

  13. HOLZER J, KARLINER JS, O´ROURKE RA, PITT W, ROSS J: Effectiveness of dopamine in patients with cardiogenic shock. Am J Cardiol 1973; 32: 79-84.

  14. GOLDBERG LI, HSIEH YY, RESNEKOV L: Newer catecholamines for treatment of heart failure and shock: an update on dopamine and first look at dobutamine. Prog Cardiovasc Dis 1977; 19: 327-340.

  15. MOYER J, SKELTON J, MILLIS L: Norepinephrine: effect in normal subjects; use in treatment of shock unresponsive to other measures. Am J Med 1953; 15: 330-343.

  16. TUTTLE RR, MILLIS J: Dobutamine: development of a new catecholamine to selective increase cardiac contractility. Circ Res 1975; 36: 185-196.

  17. GILLESPIE TA, AMBOS HD, SOBEL BE, ROBERTS R: Effects of dobutamine in patients with acute myocardial infarction. Am J Cardiol 1977; 39: 588-594.

  18. KEUNG EC, SISKIND SJ, SONNEBLICK EH, RIBNER HS, SCHWARTZ WJ, LEJEMTEL TH: Dobutamine therapy in acute myocardial infarction. JAMA 1981; 245: 144-146.

  19. BENOTTI JR, GROSSMAN W, BRAUNWALD E, DAVALOS DD, ALOUSI AA: Hemodynamic assessment of amrinone. A new inotropic agent. N Engl J Med 1978; 299: 1373-1377.

  20. MILLARD RW, DUBE G, GRUPP G, GRUPP I, ALOUSI A, SCHWARTZ A: Direct vasodilator and positive inotropic actions of amrinone. J Moll Cell Cardiol 1980; 12: 647-652.

  21. JASKI BE, FIFER MA, WRIGHT RF, BRAUNWALD E, COLUCCI WS: Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. J Clin Invest 1985; 75: 643-649.

  22. GAGE J, RUTMAN H, LUCIDO D, LEJEMTEL TH: Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. Circulation 1986; 74: 367-373.

  23. BRISTOW MR, GINSBURG R, MINOBE W, CIBICCIOTTI RS, SAGEMAN WS, ET AL: Decreased catecholamine sensitivity an beta –adrenergic –receptor density in failing human hearts. N Engl J Med 1982; 307: 205-211.

  24. COHN JN , BURKE LP: Nitroprusside. Ann Intern Med 1979; 91: 752-757.

  25. FLAHERTY JT, BECKER LC, BULKLEY BH, WEISS JL, ET AL: A randomized trial of intravenous nitroglycerin in patients with acute myocardial infarction. Circulation 1983; 68: 576-588.

  26. CHATTERJEE K: Vasodilator therapy for heart failure. Ann Intern Med 1975; 83: 421-423.

  27. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682.

  28. Gruppo Italiano per lo Studio Della Streptochinasi Nell’Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 2: 397-402.

  29. ISIS-2 Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-360.

  30. SANBORN TA, SLEEPER LA, BATES ER, ET AL: Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. Should we emergently revascularize Occluded Coronaries for cardiogenic shock? J Am Coll Cardiol 2000; 36(3 Suppl A): 1123-1129.

  31. HOCHMAN JS, SLEEPER LA, WHITE HD, ET AL: One-year survival following early revascularization for cardiogenic shock. JAMA 2001; 285: 190-192.

  32. HOCHMAN JS, SLEEPER LA, WEBB JG, ET AL: Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 1999; 341: 625-634.

  33. HOCHMAN JS: Cardiogenic Shock Complicating Acute Myocardial Infarction. Expanding the Paradigm. Circulation 2003; 107: 2998-3002.

  34. COTTER G, BLATT A, KALUSKI E, ET AL: LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J 2003; 24; 1287-1295.

  35. ARGENZIANO M, CHEN JM, CHOUDHRI AF, ET AL: Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. Thorac Cardiovasc Surg 1998; 116: 973-980.

  36. HOLMES CL, PATEL B, RUSSELL JA, WALLEY KR: Physiology of vasopressin relevant to management of septic shock. Chest 2001; 120: 989-1002.




2020     |     www.medigraphic.com